Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

Genotoxic impurities (GTIs) have recently challenged the pharmaceutical industry by virtue of their presence at a level of parts per million (ppm) in drug products, especially in high dosage molecules like Ranolazine, which has a prescribed maximum daily dosage (MDD) of 2000 mg.

In this whitepaper, we talk about steps taken by Dr. Reddy's during the product development phase to address this challenge by designing the process in such a way that all these PGIs / GTI’s are within the control in the manufacturing approach followed by Dr. Reddy’s for Ranolazine.

Read our latest whitepaper on this topic by filling the contact form below.

You can also explore our Ranolazine API offering by clicking on the link below:

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit